eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
7/2008
 
Share:
Share:
more
 
 
abstract:

Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

Jakub Żołnierek, Paweł Nurzyński, Przemysław Langiewicz, Sylwia Oborska, Anna Waśko-Grabowska, Ewa Kusztal, Beata Obrocka, Cezary Szczylik

Współczesna Onkologia (2008) vol. 12; 7 (308–313)

Background: This single-centre retros-pective analysis of data from three randomized studies and two expanded-access studies compared the effect of interferon (IFN)-alpha, sunitinib, and sorafenib on the occurrence and progression of metastatic bone lesions in patients with renal cell carcinoma (RCC).
Material and methods: In total, 292 patients were included in the analysis; 107 received sunitinib 50 mg/day in 6-week cycles (Schedule 4/2), 147 received sorafenib 800 mg/day, and 38 received placebo or IFN-alpha 9 MU three times per week.
Results: Pre-existing metastatic bone lesions were reported in 82 patients, of which 30 experienced progression. Twenty-three of 210 patients developed new bone lesions during the study. Overall, sunitinib appeared slightly more effective than sorafenib or IFN-alpha at extending mean time to progression of pre-existing bone lesions (p=0.057). Compared with sorafenib, sunitinib significantly decreased formation (p=0.034) and prolonged time to occurrence of new bone lesions (p=0.047).
Conclusions: Further evaluation of the effect of these therapies on bone metastases in RCC is warranted.
keywords:

renal cell carcinoma, sunitinib malate, sorafenib tosylate, IFN-alpha, metastasis

Quick links
© 2015 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe